Business
SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
REDMOND, Wash. & PRINCETON, N.J., February 26, 2026--SystImmune and BMS Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously-Treated Unresectable...
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":597,"height":217,"url":"https://media.zenfs.com/en/business-wire.com/a48861f9cd8eb03209aac3a27a67ad9f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/SNLTYjQxCUMv0fPqlEkWbg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM0OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/a48861f9cd8eb03209aac3a27a67ad9f","width":597,"height":217}},"lazy":false},{"type":"text","content":"Izalontamab brengitecan (Iza-bren) met its dual primary endpoints of progression free survival ("PFS") and overall survival ("OS") in an interim analysis of a Phase 3 trial (NCT06382142) conducted in China","length":225,"tagName":"p","attribs":{}},{"type":"text","content":"BL-B01D1-307 is the third Phase III study in which iza-bren has achieved its primary endpoint(s)","length":96,"tagName":"p","attribs":{}},{"type":"text","content":"REDMOND, Wash. & PRINCETON, N.J., February 26, 2026--(BUSINESS WIRE)--SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced that SystImmune’s parent company, Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin), reported positive topline results from a pre-specified interim analysis of a Phase III study (BL-B01D1-307) evaluating izalontamab brengitecan (iza-bren), an EGFR×HER3 bispecific antibody-drug conjugate (ADC), in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose disease progressed following prior taxane therapy.","length":646,"tagName":"p"},{"type":"text","content":"In the pre-specified interim analysis, topline results showed that iza-bren demonstrated statistically significant and clinically meaningful improvement in both progression-free survival (PFS) and overall survival (OS) compared to chemotherapy of physician’s choice, meeting both dual primary endpoints.","length":303,"tagName":"p"},{"type":"text","content":"This Phase III study represents the third Phase III trial in which iza-bren has achieved its primary endpoint(s). It is the first bispecific ADC in a Phase III study to report dual positive PFS/OS results in the treatment of triple-negative breast cancer.","length":255,"tagName":"p"},{"type":"text","content":""Patients with advanced tripl...